Unknown

Dataset Information

0

Type II secretory phospholipase A2 and prognosis in patients with stable coronary heart disease: mendelian randomization study.


ABSTRACT: Serum type II secretory phospholipase A(2) (sPLA(2)-IIa) has been found to be predictive of adverse outcomes in patients with stable coronary heart disease. Compounds targeting sPLA(2)-IIa are already under development. This study investigated if an association of sPLA(2)-IIa with secondary cardiovascular disease (CVD) events may be of causal nature or mainly a matter of confounding by correlated cardiovascular risk markers.Eight-year follow-up data of a prospective cohort study (KAROLA) of patients who underwent in-patient rehabilitation after an acute cardiovascular event were analysed. Associations of polymorphisms (SNP) in the sPLA(2)-IIa-coding gene PLA2G2A with serum sPLA(2)-IIa and secondary fatal or non-fatal CVD events were examined by multiple regression. Hazard ratios (HR) were compared with those expected if the association between sPLA(2)-IIa and CVD were causal. The strongest determinants of sPLA(2)-IIa (rs4744 and rs10732279) were associated with an increase of serum concentrations by 81% and 73% per variant allele. HRs (95% confidence intervals) estimating the associations of the SNPs with secondary CVD events were increased, but not statistically significant (1.16 [0.89-1.51] and 1.18 [0.91-1.52] per variant allele, respectively). However, these estimates were very similar to those expected when assuming causality (1.18 and 1.17), based on an association of natural log-transformed sPLA(2)-IIa concentration with secondary events with HR?=?1.33 per unit.The present findings regarding genetic polymorphisms, determination of serum sPLA(2)-IIa, and prognosis in CVD patients are consistent with a genuine causal relationship and thus might point to a valid drug target for prevention of secondary CVD events.

SUBMITTER: Breitling LP 

PROVIDER: S-EPMC3142130 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature

altmetric image

Publications

Type II secretory phospholipase A2 and prognosis in patients with stable coronary heart disease: mendelian randomization study.

Breitling Lutz P LP   Koenig Wolfgang W   Fischer Marcus M   Mallat Ziad Z   Hengstenberg Christian C   Rothenbacher Dietrich D   Brenner Hermann H  

PloS one 20110722 7


<h4>Background</h4>Serum type II secretory phospholipase A(2) (sPLA(2)-IIa) has been found to be predictive of adverse outcomes in patients with stable coronary heart disease. Compounds targeting sPLA(2)-IIa are already under development. This study investigated if an association of sPLA(2)-IIa with secondary cardiovascular disease (CVD) events may be of causal nature or mainly a matter of confounding by correlated cardiovascular risk markers.<h4>Methodology/principal findings</h4>Eight-year fol  ...[more]

Similar Datasets

| S-EPMC4212409 | biostudies-literature
| S-EPMC3826105 | biostudies-literature
| S-EPMC5841831 | biostudies-other
| S-EPMC4959825 | biostudies-literature
| S-EPMC6557629 | biostudies-literature
| S-EPMC2758888 | biostudies-literature
| S-EPMC6510421 | biostudies-literature
| S-EPMC3119755 | biostudies-literature
| S-EPMC7196469 | biostudies-literature